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lead aVR in patients with ACS. More adverse events existed in ST-
segment elevation of aVR. The prognosis in other groups has better
clinical results.
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BACKGROUND It is unclear whether the routine follow up (FU) cor-
onary angiography (CAG) regardless of patient’s symptoms after
successful primary percutaneous coronary intervention (PCI) with
drug-eluting stents (DESs) in acute ST elevation myocardial infarction
(STEMI) patients (pts) is beneﬁcial or not.
METHODS The study population consisted of 447 consecutive STEMI
patients (pts) underwent PCI with unrestricted utilization of DESs
from January 2004 to May 2011. Routine FU CAG was performed be-
tween 6 to 9 months following index PCI and was decided by indi-
vidual physician’s discretion. Rests of the pts were clinically followed
and ischemic driven events were captured. Clinical events including
mortality, myocardial infarction (MI) and clinically driven PCI before 9
months were excluded in both groups. Cumulative clinical outcomes
up to 3 years were compared between the Routine CAG group (n ¼ 244
pts) and Clinical FU group (n ¼ 203 pts). To adjust potential con-
founders, a propensity score matched (PSM) analysis was performed
using the logistic regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (129 pairs,
n ¼ 258 pts, C-statistic ¼ 0.762) were generated and the baseline
characteristics of the two groups were balanced. At 3 years, the inci-
dence of individual hard endpoints including mortality, MI, major
adverse cardiac events (MACEs) were similar between the two groups
excepted that Routine CAG group had higher incidence of any revas-
cularization, particularly non-target vessel revascularization (NTVR)
than the control group (Table).
CONCLUSION Despite the expected beneﬁcial effects, routine FU CAG
following index primary PCI with DESs in STEMI pts was associated
with higher incidence of repeat PCI including NTVR up to 3-year
clinical follow-up.TCTAP A-008
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BACKGROUND We compared the efﬁcacy and safety of sirolimus-
eluting stents with Parylene C (SESs), everolimus-eluting stents with
poly n-butyl methacrylate (EESs), biodegradable stent (BP-DESs), and
endothelial progenitor cell capture stents (EPCCSs).
METHODS From the IRIS-DES registry, we identiﬁed 1517 patients
treated using PCI with SESs (N ¼ 372), EESs (N ¼ 405), BP-DESs (N ¼
300), and EPCCSs (N ¼ 440) in ST-elevation myocardial infarction
(STEMI). Major adverse cardiac events (MACE) were deﬁned using
composite of death, myocardial infarction, and target vessel revas-
cularization at 24 months.
RESULTS The average number of stent used was 1.6  0.8. At 2 years,
there was no difference in the incidence of MACE (8.5% in SESs, 9.9%
in EES, 10.2% in BP-DES, and 12.8% in EPCCS, P ¼ 0.281), death (5.0%
in SESs, 4.3% in EES, 4.4%in BP-DES, and 6.2% in EPCCS, P ¼ 0.718),
MI (0.6% in SESs, 1.6% in EES, 1.5%in BP-DES, and 1.5% in EPCCS, P ¼
0.572), and TVR (3.8% in SESs, 5.9% in EES, 4.8% in BP-DES, and 6.5%
in EPCCS, P ¼ 0.313). The EPCCSs group showed trend of higher rate in
any revascularization, but no signiﬁcantly statistical difference (6.6%
in SESs, 9.1% in EES, 7.2% in BP-DES, and 11.6% in EPCCS, P ¼ 0.313).
The cumulative rates of Academic Research Consortium deﬁned def-
inite stent thrombosis were 0.3% in SESs, 1.2% in EESs, 0.7% in BP-
DESs, and 1.6% in EPCCSs (P ¼ 0.239).
CONCLUSION The 4 different DESs showed no signiﬁcant difference
in clinical outcome at 2-year follow-up in patients with STEMI.
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eluting
stentEverlimus-
eluting
stentBiodegradable
polymer stentEndothelial cell
capture coating
stentP-value(N [ 372) (N [ 405) (N [ 300) ( N [ 440)Clinical characteristicsAge, years 61.8  12.2 61.3  13.4 61.0  11.6 62.1 11.7 0.638
Male sex 282 (76%) 313(77%) 247(82%) 347(79%) 0.211Body mass index 24.2  3.3 24.2  3.3 24.1  2.9 24.1  3.2 0.969
Diabetes 108 (29%) 112 (27%) 72 (24%) 111 (25%) 0.422Hypertension 178 (48%) 210 (52%) 144 (48$) 215 (49%) 0.739Hyperlipidemia 97 (26%) 118 (29%) 72 (24%) 139 (32%) 0.104Previous PCI 38 (10%) 33 (8%) 13 (4%) 23 (5%) 0.007Previous
myocardial
infarction32 (9%) 16 (4%) 12 (4%) 17 (4%) 0.005Previous
congestive
heart failure9 (2%) 10 (3%) 3 (1%) 5 (1%) 0.258Previous CABG 5 (1%) 3 (1%) 1 (1%) 0 (0%) 0.083Chronic renal
failure8 (2%) 9 (2%) 5 (2%) 8 (2%) 0.944Peripheral
vascular
disease4 (1%) 3 (1%) 1 (1%) 1 (1%) 0.398Chronic
obstructive
pulmonary
disease10 (3%) 15 (4%) 5 (2%) 8 (2%) 0.253Angiographic characteristicsNumber of
diseased
vessels< 0.001Single vessel
disease170 (46%) 221 (54%) 174 (58%) 271 (62%)Two vessel
disease111 (30%) 109 (27%) 79 (26%) 117 (27%)Triple vessel
disease78 (21%) 59 (15%) 42 (14%) 46 (11%)Left main
involvement13 (4%) 19 (5%) 5 (2%) 6 (1%)Multivessel
disease202 (54%) 187 (46%) 126 (42%) 169 (38%) < 0.001Procedure characteristicsNumber of stent 1.6  0.9 1.6  0.9 1.3  0.6 1.4  0.5 < 0.001
Average
diameter of
stent (mm)3.2 0.5 3.4 0.6 3.3 0.6 3.5 0.6 <0.001Total stent
length (mm)42.5 25.7 35.5 21.9 27.8 14.2 29.3 14.7 <0.001Antiplatelet agentDual antiplatelet
agent at
discharge350
(99.4%)378
(99.0%)264 (92%) 391
(94.2%)< 0.001Table 2. Cumulative incidence rate of clinical outcome at 2 yearsTCTAP A-009
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BACKGROUND The aimof this studywas to evaluate the clinical outcome
of preventive angioplasty in ST-elevation Myocardial Infarction.
